Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : SGS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
SGS’s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease
Details : Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : SGS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?